Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06981325 |
| Title | Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients (CEMI-first) |
| Acronym | CEMI-first |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | DEU |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Helios Klinikum Erfurt | RECRUITING | Erfurt | Germany | Details | ||
| Universitätsklinikum Erlangen | RECRUITING | Erlangen | Germany | Details | ||
| Nationales Centrum für Tumorerkrankungen (NCT) | RECRUITING | Heidelberg | Germany | Details | ||
| Universitätsklinikum Leipzig | RECRUITING | Leipzig | Germany | Details | ||
| Johannes Wesling Klinikum | RECRUITING | Minden | Germany | Details | ||
| Helios Klinikum Oberhausen | RECRUITING | Oberhausen | Germany | Details | ||
| Universitätsklinikum Tübingen | RECRUITING | Tübingen | Germany | Details |